Penumbra Inc(PEN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PEN Penumbra Inc

交易中 12-16 13:09:41 EST

310.02

+0.87

+0.28%

最高314.10	最低307.00	成交量23.98万
今开309.89	昨收309.15	日振幅2.30%
总市值121.41亿	流通市值117.28亿	总股本3,916万
成交额7,467万	换手率0.63%	流通股本3,783万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PEN","market":"US","secType":"STK","nameCN":"Penumbra Inc","latestPrice":310.02,"timestamp":1765908575548,"preClose":309.15,"halted":0,"volume":239791,"delay":0,"floatShares":37828804,"shares":39162177,"eps":4.138256,"marketStatus":"交易中","change":0.87,"latestTime":"12-16 13:09:41 EST","open":309.89,"high":314.1,"low":307,"amount":74674480.69426,"amplitude":0.022966,"askPrice":310.28,"askSize":19,"bidPrice":309.22,"bidSize":33,"shortable":3,"etf":0,"ttmEps":4.138256,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765918800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1442548800000,"exchange":"NYSE","adjPreClose":309.15,"preHourTrading":{"tag":"盘前","latestPrice":307,"preClose":309.15,"latestTime":"04:51 EST","volume":1,"amount":307,"timestamp":1765878683228},"postHourTrading":{"tag":"盘后","latestPrice":309.15,"preClose":309.15,"latestTime":"17:58 EST","volume":13074,"amount":4041826.23,"timestamp":1765839535662},"volumeRatio":0.782094,"impliedVol":0.3565,"impliedVolPercentile":0.112},"requestUrl":"/m/hq/s/PEN","defaultTab":"news","newsList":[{"id":"1122749407","title":"异动解读 | 业绩超预期、分析师上调目标价，Penumbra盘中大涨13.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=1122749407","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122749407?lang=zh_cn&edition=full","pubTime":"2025-07-30 22:35","pubTimestamp":1753886158,"startTime":"0","endTime":"0","summary":"7月30日盘中，医疗器械公司Penumbra Inc股价出现显著上涨，截至10:33，涨幅达13.66%。根据公司公告，Penumbra在2025年第二季度实现收入3.395亿美元，同比增长13.4%，超过分析师预期的3.2777亿美元。除了强劲的财务业绩外，Penumbra还上调了2025年全年收入指引至13.55亿美元至13.7亿美元区间，高于此前分析师预期的13.54亿美元。受此影响，多家券商分析师调整了对Penumbra的目标价。综上所述，Penumbra的股价大幅上涨主要是由于其超预期的季度业绩、乐观的全年指引以及分析师的积极评级共同推动。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"28bca3b2321cb6bcac82c18af094c366","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PEN"],"gpt_icon":0},{"id":"1135798786","title":"异动解读 | 业绩超预期，Penumbra盘前大涨13.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135798786","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135798786?lang=zh_cn&edition=full","pubTime":"2025-07-30 20:02","pubTimestamp":1753876973,"startTime":"0","endTime":"0","summary":"7月30日周三，医疗器械公司Penumbra Inc在盘前交易中股价大幅上涨13.58%，这一显著涨幅主要源于公司发布的强劲第二季度财报。除了强劲的财务业绩外，Penumbra还上调了2025年全年收入指引至13.55亿美元至13.7亿美元区间，高于此前分析师预期的13.54亿美元。公司维持了美国血栓切除业务相比2024年水平增长20%至21%的指引。这一积极展望进一步提振了投资者信心，推动股价大幅上涨。受此影响，多家券商分析师调整了对Penumbra的目标价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PEN"],"gpt_icon":1},{"id":"1141435130","title":"异动解读 | Penumbra股价夜盘飙升11.82%，第二季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1141435130","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141435130?lang=zh_cn&edition=full","pubTime":"2025-07-30 14:26","pubTimestamp":1753856800,"startTime":"0","endTime":"0","summary":"领先的血栓切除设备制造商Penumbra Inc在周三夜盘交易中股价大涨11.82%，这一显著涨幅源于公司发布的强劲第二季度财报。根据公司公告，Penumbra在2025年第二季度实现收入3.395亿美元，同比增长13.4%，超过分析师预期的3.2777亿美元。值得注意的是，Penumbra还上调了2025年全年收入指引至13.55亿美元至13.7亿美元区间，高于此前分析师预期的13.54亿美元。公司维持了美国血栓切除业务相比2024年水平增长20%至21%的指引。这一积极展望进一步提振了投资者信心，推动股价大幅上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PEN"],"gpt_icon":1},{"id":"2517248471","title":"商务部新闻发言人就《中国的芬太尼类物质管控》白皮书答记者问","url":"https://stock-news.laohu8.com/highlight/detail?id=2517248471","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517248471?lang=zh_cn&edition=full","pubTime":"2025-03-07 20:30","pubTimestamp":1741350655,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月7日，商务部新闻发言人就《中国的芬太尼类物质管控》白皮书答记者问。商务部新闻发言人指出，白皮书充分说明美方以芬太尼为由对中国产品加征20%关税是毫无根据的，是典型的保护主义、单边主义和霸凌主义行径。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4548","PEN","BK4082"],"gpt_icon":0},{"id":"2516629235","title":"《中国的芬太尼类物质管控》白皮书发布！外交部回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2516629235","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516629235?lang=zh_cn&edition=full","pubTime":"2025-03-04 18:24","pubTimestamp":1741083846,"startTime":"0","endTime":"0","summary":"近年来，中国高度重视芬太尼类物质管控","market":"sg","thumbnail":"https://img3.gelonghui.com/4c36a-89a8ef34-1fb6-47d6-b372-9a2aca034cb6.jpg?guru_height=851&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/4c36a-89a8ef34-1fb6-47d6-b372-9a2aca034cb6.jpg?guru_height=851&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1849501","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4548","BK4082","CDC","BK4196","EUDA","PEN"],"gpt_icon":0},{"id":"2512872614","title":"Truist Securities：维持Penumbra(PEN.US)评级，由买入调整至买入评级, 目标价由285.00美元调整至325.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512872614","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512872614?lang=zh_cn&edition=full","pubTime":"2025-02-20 01:21","pubTimestamp":1739985687,"startTime":"0","endTime":"0","summary":"Truist Securities：维持Penumbra(PEN.US)评级，由买入调整至买入评级, 目标价由285.00美元调整至325.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/20012148268177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PEN"],"gpt_icon":0},{"id":"1173379702","title":"异动解读 | Penumbra第四季度业绩大超预期,多家机构力挺看涨9.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173379702","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173379702?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:33","pubTimestamp":1739975623,"startTime":"0","endTime":"0","summary":"当前市场环境动荡,但医疗设备制造商Penumbra Inc.依然在周三早盘大涨9.21%,股价一度涨至293.90美元。引发该股价大涨的主要原因是该公司第四季度业绩优异且分析师看好其未来前景。Penumbra昨日公布第四季度营收达3.15亿美元,同比增长10.8%,超出分析师预期的3.11亿美元。财报理想导致多家分析机构上调对Penumbra的目标价和评级。包括BTIG、Canaccord Genuity、摩根大通等14家机构上调目标价,目标价中位数达308美元,最高预期340美元。看涨情绪推动Penumbra股价大涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PEN"],"gpt_icon":0},{"id":"2512565488","title":"瑞银：维持Penumbra(PEN.US)评级，由买入调整至买入评级, 目标价由305.00美元调整至320.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512565488","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512565488?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:31","pubTimestamp":1739975484,"startTime":"0","endTime":"0","summary":"瑞银：维持Penumbra(PEN.US)评级，由买入调整至买入评级, 目标价由305.00美元调整至320.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19223148266869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PEN"],"gpt_icon":0},{"id":"2512483349","title":"Penumbra, Inc.盘中异动 股价大涨9.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512483349","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512483349?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:30","pubTimestamp":1739975444,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时30分，Penumbra, Inc.股票出现波动，股价大幅拉升9.21%。Penumbra, Inc.股票所在的医疗器械行业中，整体涨幅为0.00%。其相关个股中，Sintx Technologies, Inc.、Reshape Lifesciences, Inc.、Naya Biosciences, Inc.涨幅较大，Sintx Technologies, Inc.、Reshape Lifesciences, Inc.、Tivic Health Systems, Inc.较为活跃，换手率分别为2563.13%、291.89%、4.27%，振幅较大的相关个股有Beyond Air, Inc.、Reshape Lifesciences, Inc.、Sintx Technologies, Inc.，振幅分别为4.05%、3.68%、3.54%。Penumbra, Inc.公司简介：Penumbra Inc 为神经血管和外周血管市场开发和制造医疗设备。Penumbra 的大部分收入来自美国。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223045abd4fdbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223045abd4fdbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","PEN","BK4548"],"gpt_icon":0},{"id":"2512001831","title":"Piper Sandler：重申Penumbra(PEN.US)评级，由增持调整至增持评级, 目标价由250.00美元调整至330.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512001831","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512001831?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:01","pubTimestamp":1739973670,"startTime":"0","endTime":"0","summary":"Piper Sandler：重申Penumbra(PEN.US)评级，由增持调整至增持评级, 目标价由250.00美元调整至330.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19220148266760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PEN"],"gpt_icon":0},{"id":"2512310465","title":"大摩：维持Penumbra(PEN.US)评级，由持股观望调整至持股观望评级, 目标价由240.00美元调整至260.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512310465","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512310465?lang=zh_cn&edition=full","pubTime":"2025-02-19 21:13","pubTimestamp":1739970809,"startTime":"0","endTime":"0","summary":"大摩：维持Penumbra(PEN.US)评级，由持股观望调整至持股观望评级, 目标价由240.00美元调整至260.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19211348266463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PEN"],"gpt_icon":0},{"id":"1129444428","title":"异动解读 | Penumbra 公司盘前涨逾8%,受公司财报超预期和分析师看涨影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1129444428","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129444428?lang=zh_cn&edition=full","pubTime":"2025-02-19 21:02","pubTimestamp":1739970161,"startTime":"0","endTime":"0","summary":"周三早盘,Penumbra 公司股价出现8.14%的大涨幅度,引发了投资者的广泛关注。\n\n财报数据显示,该医疗器械公司第四季度营收同比增长10.8%至3.15亿美元,超过了分析师此前3.12亿美元的预期。公司近年来在多个利基领域取得积累,深受市场看好。\n\n财报公布后,多家分析机构上调了该股目标价,看好公司未来表现。摩根大通分析师认为,Penumbra公司今年的销售额将继续保持适度增长,利润率也将大幅提高,基本业务表现良好。目标价由230美元上调至285美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Penumbra 公司盘前涨逾8%,受公司财报超预期和分析师看涨影响","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PEN"],"gpt_icon":0},{"id":"2512101345","title":"Needham：重申Penumbra(PEN.US)评级，由持有调整至持有评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512101345","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512101345?lang=zh_cn&edition=full","pubTime":"2025-02-19 20:40","pubTimestamp":1739968851,"startTime":"0","endTime":"0","summary":"Needham：重申Penumbra(PEN.US)评级，由持有调整至持有评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19204048266027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PEN"],"gpt_icon":0},{"id":"2512010136","title":"Baird：维持Penumbra(PEN.US)评级，由优于大市调整至优于大市评级, 目标价由305.00美元调整至328.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512010136","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512010136?lang=zh_cn&edition=full","pubTime":"2025-02-19 20:40","pubTimestamp":1739968851,"startTime":"0","endTime":"0","summary":"Baird：维持Penumbra(PEN.US)评级，由优于大市调整至优于大市评级, 目标价由305.00美元调整至328.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19204048266026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PEN"],"gpt_icon":0},{"id":"1125223106","title":"异动解读 | 业绩超预期 Penumbra股价盘后大涨6.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125223106","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125223106?lang=zh_cn&edition=full","pubTime":"2025-02-19 06:08","pubTimestamp":1739916514,"startTime":"0","endTime":"0","summary":"Penumbra Inc在周二盘后交易中大涨6.29%,引发了市场的广泛关注。公司此前公布的2024年第四季度财报业绩出色,超出了华尔街分析师的预期,这是导致股价上扬的主要推动力。具体来看,Penumbra公司第四季度实际营收为3.1552亿美元,同比增长10.8%,高于分析师平均预期3.1152亿美元。分析师普遍给予该股\"买入\"评级,平均12个月目标价达到262美元。作为一家领先的医疗设备制造商,Penumbra在肿瘤介入治疗和神经介入领域享有广阔的市场机遇,增长空间依旧可期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PEN"],"gpt_icon":0},{"id":"1119656040","title":"Penumbra第四季度调整后每股收益$0.97，超出预期$0.90，销售额为$3.1552亿，超出预期$3.1155亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1119656040","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119656040?lang=zh_cn&edition=full","pubTime":"2025-02-19 05:21","pubTimestamp":1739913704,"startTime":"0","endTime":"0","summary":"Penumbra  报告季度每股收益为$0.97，比分析师一致预期的$0.90高出7.78%。这比去年同期的每股收益$0.76增长了27.63%。以上内容来自Benzinga Earnings专栏，原文如下：Penumbra  reported quarterly earnings of $0.97 per share which beat the analyst consensus estimate of $0.90 by 7.78 percent. This is a 27.63 percent increase over earnings of $0.76 per share from the same period last year.  The company reported quarterly sales of $315.52 million which beat the analyst consensus estimate of $311.55 million by 1.27 percent.  This is a 10.83 percent increase over","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Penumbra第四季度调整后每股收益$0.97，超出预期$0.90，销售额为$3.1552亿，超出预期$3.1155亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEN"],"gpt_icon":0},{"id":"2503358867","title":"Penumbra, Inc.盘中异动 大幅跳水5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503358867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503358867?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:31","pubTimestamp":1736778664,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时31分，Penumbra, Inc.股票出现波动，股价快速跳水5.18%。Penumbra, Inc.股票所在的医疗器械行业中，整体跌幅为0.37%。其相关个股中，Standard Biotools Inc.、迪卡斯、Apyx Medical Corporation涨幅较大，Reshape Lifesciences, Inc.、Catheter Precision, Inc.、Naya Biosciences, Inc.较为活跃，换手率分别为3.45%、3.36%、2.76%，振幅较大的相关个股有Biomerica, Inc.、布鲁克、盈美特，振幅分别为100.00%、99.69%、99.62%。Penumbra, Inc.公司简介：Penumbra Inc 为神经血管和外周血管市场开发和制造医疗设备。Penumbra 的大部分收入来自美国。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223104aba93025&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223104aba93025&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","PEN","BK4548"],"gpt_icon":0},{"id":"2501884277","title":"Penumbra, Inc.盘中异动 早盘股价大涨5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501884277","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501884277?lang=zh_cn&edition=full","pubTime":"2025-01-07 22:31","pubTimestamp":1736260301,"startTime":"0","endTime":"0","summary":"北京时间2025年01月07日22时31分，Penumbra, Inc.股票出现波动，股价急速上涨5.34%。Penumbra, Inc.股票所在的医疗器械行业中，整体涨幅为0.22%。其相关个股中，Inari Medical, Inc.、Anteris Technologies Global Corp.、Monogram Technologies Inc.涨幅较大，Nanovibronix, Inc.、Lifeward Ltd.、Adagio Medical Holdings, Inc较为活跃，换手率分别为16.21%、10.91%、3.97%，振幅较大的相关个股有Venus Concept Inc.、Vicarious Surgical Inc.、拜尔德医疗，振幅分别为7.79%、7.06%、6.97%。Penumbra, Inc.公司简介：Penumbra Inc 为神经血管和外周血管市场开发和制造医疗设备。Penumbra 的大部分收入来自美国。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107223141aba1defe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107223141aba1defe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","PEN","BK4548"],"gpt_icon":0},{"id":"2501298202","title":"Penumbra, Inc.盘中异动 大幅下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501298202","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501298202?lang=zh_cn&edition=full","pubTime":"2025-01-07 04:21","pubTimestamp":1736194886,"startTime":"0","endTime":"0","summary":"北京时间2025年01月07日04时21分，Penumbra, Inc.股票出现异动，股价急速下挫5.00%。Penumbra, Inc.股票所在的医疗器械行业中，整体涨幅为0.02%。其相关个股中，Ainos Inc C/Wts 29/07/2027 、Heartsciences Inc C/Wts 、Envoy Medical Inc C/Wts 29/09/2028 涨幅较大，Nanovibronix, Inc.、古特拉、Naya Biosciences, Inc.较为活跃，换手率分别为1541.06%、92.71%、69.99%，振幅较大的相关个股有Ainos Inc C/Wts 29/07/2027 、Nanovibronix, Inc.、古特拉，振幅分别为169.61%、112.38%、96.47%。Penumbra, Inc.公司简介：Penumbra Inc 为神经血管和外周血管市场开发和制造医疗设备。Penumbra 的大部分收入来自美国。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107042127a217def4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107042127a217def4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","PEN","BK4548"],"gpt_icon":0},{"id":"2490868980","title":"Penumbra, Inc.盘中异动 早盘大幅上涨5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490868980","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490868980?lang=zh_cn&edition=full","pubTime":"2024-12-11 22:36","pubTimestamp":1733927778,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日22时36分，Penumbra, Inc.股票出现异动，股价快速上涨5.23%。Penumbra, Inc.股票所在的医疗器械行业中，整体涨幅为0.28%。其相关个股中，Quantum-Si Incorporated、Senseonics Holdings, Inc.、Biosig Technologies, Inc.涨幅较大，Nanovibronix, Inc.、Quantum-Si Incorporated、Bluejay Diagnostics, Inc.较为活跃，换手率分别为206.59%、8.19%、5.22%，振幅较大的相关个股有Nanovibronix, Inc.、Quantum-Si Incorporated、Outset Medical, Inc.，振幅分别为14.50%、12.39%、10.07%。Penumbra, Inc.公司简介：Penumbra Inc 为神经血管和外周血管市场开发和制造医疗设备。Penumbra 的大部分收入来自美国。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223618984b560d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211223618984b560d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4082","PEN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.penumbrainc.com","stockEarnings":[{"period":"1week","weight":0.0486},{"period":"1month","weight":0.1038},{"period":"3month","weight":0.1757},{"period":"6month","weight":0.2029},{"period":"1year","weight":0.259},{"period":"ytd","weight":0.3018}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Penumbra, Inc.于2004年作为特拉华州公司成立。该公司是一家全球性介入治疗公司，专注于设计，开发，制造和销售创新的医疗设备。公司拥有解决具有挑战性的医疗条件和跨越两大市场显著的临床需求，神经及周围血管有广泛的产品组合。它的产品地址包括缺血性中风，出血性中风，以及可以通过血栓和栓塞程序待治疗各种周围血管。","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.076515},{"month":2,"riseRate":0.6,"avgChangeRate":0.022235},{"month":3,"riseRate":0.5,"avgChangeRate":0.012648},{"month":4,"riseRate":0.7,"avgChangeRate":0.020061},{"month":5,"riseRate":0.3,"avgChangeRate":-0.011126},{"month":6,"riseRate":0.6,"avgChangeRate":0.018151},{"month":7,"riseRate":0.5,"avgChangeRate":0.028062},{"month":8,"riseRate":0.6,"avgChangeRate":0.024735},{"month":9,"riseRate":0.4,"avgChangeRate":-0.00132},{"month":10,"riseRate":0.454545,"avgChangeRate":0.011236},{"month":11,"riseRate":0.727273,"avgChangeRate":0.089166},{"month":12,"riseRate":0.545455,"avgChangeRate":-0.001824}],"exchange":"NYSE","name":"Penumbra Inc","nameEN":"Penumbra"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Penumbra Inc(PEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Penumbra Inc(PEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Penumbra Inc,PEN,Penumbra Inc股票,Penumbra Inc股票老虎,Penumbra Inc股票老虎国际,Penumbra Inc行情,Penumbra Inc股票行情,Penumbra Inc股价,Penumbra Inc股市,Penumbra Inc股票价格,Penumbra Inc股票交易,Penumbra Inc股票购买,Penumbra Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Penumbra Inc(PEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Penumbra Inc(PEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}